Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More
Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren's disease (SjD) with its drug, nipocalimab. In ... Read More
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of ... Read More
Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific ... Read More
Jury awards $45m in damages in asbestos-related lawsuit against Johnson & Johnson
In a landmark decision, the Circuit Court of Cook County in Chicago has found Johnson & Johnson (NYSE: JNJ) and two of its subsidiaries, Johnson ... Read More
Johnson & Johnson announces $13.1bn acquisition of Shockwave Medical to strengthen medtech division
In a monumental move within the medical technology sector, Johnson & Johnson (NYSE: JNJ) has announced its acquisition of Shockwave Medical, Inc. (Nasdaq: SWAV) for ... Read More
Nanobiotix achieves milestone in cancer treatment with NBTXR3, secures $20m from Janssen
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a leader in the field of biotechnology, announced a significant achievement in its ongoing pivotal Phase 3 study, NANORAY-312. ... Read More
Bausch + Lomb acquires Johnson & Johnson Vision’s Blink product line
Bausch + Lomb, an esteemed global eye health company, has broadened its portfolio by purchasing Johnson & Johnson Vision's Blink product line for $106.5 million. ... Read More
Marksans Pharma gets FDA final approval for Famotidine Tablets
Marksans Pharma said that it has been granted final approval for the over-the-counter (OTC) use of Famotidine Tablets USP, 10 mg and 20 mg from ... Read More
Johnson & Johnson completes $17bn acquisition of Abiomed
Johnson & Johnson (J&J) has closed the previously announced acquisition of Abiomed, a medical device technology company, for an enterprise value of around $16.6bn, in ... Read More